Bronchoprotective Effect of Arformoterol in Children With Exercise-Induced Bronchospasm (EIB)

Inclusion Criteria: * Children 12-17 years of age * Physician diagnosed asthma for at least 6 months * Long term controller medication for at least 4 weeks if any being used * Females of child-bearing potential agree to use an acceptable form of birth control for the duration of the study * EIB diagnosed by a positive exercise challenge at screening * Forced expiratory volume in 1 second (FEV1) greater than 70% of predicted at screening visit Exclusion Criteria: * History of cardiac dysfunction * Inability to perform exercise challenge ( i.e., running on treadmill or performing adequate spirometry) * Upper respiratory infection in the last 4 weeks * Severe exacerbation, use of oral steroids, or hospitalization in the last 3 months * Chronic (greater than 2 weeks) use of a Long Acting Beta Agonist (LABA) * Pregnancy or lactation * History of paradoxical bronchospasm with any beta-agonist * Obesity defined as BMI greater than 30 kg/m2